Stryker Co. (NYSE:SYK) Shares Acquired by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC grew its position in Stryker Co. (NYSE:SYK - Free Report) by 20.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 80,748 shares of the medical technology company's stock after acquiring an additional 13,947 shares during the quarter. Aptus Capital Advisors LLC's holdings in Stryker were worth $29,171,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Centennial Bank AR increased its holdings in shares of Stryker by 106.7% in the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock valued at $32,000 after purchasing an additional 48 shares during the last quarter. HBW Advisory Services LLC purchased a new position in shares of Stryker during the 3rd quarter worth $42,000. Hara Capital LLC acquired a new position in shares of Stryker during the 3rd quarter valued at about $42,000. Grove Bank & Trust grew its holdings in shares of Stryker by 84.8% in the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company's stock valued at $44,000 after purchasing an additional 56 shares during the period. Finally, DT Investment Partners LLC increased its position in Stryker by 114.3% during the third quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company's stock worth $49,000 after purchasing an additional 72 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Up 2.2 %

Shares of SYK stock traded up $8.25 on Tuesday, reaching $387.11. 1,608,631 shares of the stock were exchanged, compared to its average volume of 1,254,939. Stryker Co. has a twelve month low of $276.60 and a twelve month high of $388.12. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $147.57 billion, a price-to-earnings ratio of 40.61, a PEG ratio of 2.83 and a beta of 0.91. The business's 50 day moving average price is $361.83 and its 200 day moving average price is $346.06.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter in the previous year, the firm earned $2.46 EPS. The company's revenue was up 11.9% compared to the same quarter last year. As a group, sell-side analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SYK. Morgan Stanley raised their price target on shares of Stryker from $345.00 to $350.00 and gave the stock an "equal weight" rating in a report on Monday, July 15th. Piper Sandler restated an "overweight" rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Barclays increased their price target on Stryker from $402.00 to $418.00 and gave the stock an "overweight" rating in a report on Thursday, October 31st. BTIG Research upped their target price on shares of Stryker from $383.00 to $394.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Finally, Citigroup lifted their price target on shares of Stryker from $406.00 to $411.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Stryker presently has an average rating of "Moderate Buy" and a consensus target price of $393.65.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of the company's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Kevin Lobo sold 57,313 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company's stock, valued at approximately $36,879,954.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company's stock, valued at approximately $3,685,213.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,381 shares of company stock worth $24,825,275 in the last quarter. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.